Hyperion DeFi (NASDAQ:HYPD – Get Free Report) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Thursday, Zacks reports.
A number of other research firms also recently commented on HYPD. Chardan Capital increased their price objective on shares of Hyperion DeFi from $7.30 to $8.45 and gave the company a “buy” rating in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and set a $11.20 target price (up from $7.10) on shares of Hyperion DeFi in a report on Thursday. Finally, Weiss Ratings upgraded Hyperion DeFi from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, September 1st. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $9.82.
Check Out Our Latest Stock Report on Hyperion DeFi
Hyperion DeFi Price Performance
Hyperion DeFi (NASDAQ:HYPD – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported $0.92 earnings per share for the quarter. The firm had revenue of $0.36 million for the quarter. Hyperion DeFi had a net margin of 416.56% and a negative return on equity of 11.62%. On average, equities analysts anticipate that Hyperion DeFi will post 1.78 EPS for the current fiscal year.
Institutional Trading of Hyperion DeFi
Hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC purchased a new stake in Hyperion DeFi in the fourth quarter valued at $663,000. Jane Street Group LLC purchased a new position in shares of Hyperion DeFi during the 4th quarter worth $493,000. Focus Partners Advisor Solutions LLC acquired a new stake in shares of Hyperion DeFi during the 4th quarter worth about $221,000. Geode Capital Management LLC acquired a new stake in shares of Hyperion DeFi during the 4th quarter worth about $214,000. Finally, Investment House LLC purchased a new stake in Hyperion DeFi in the 4th quarter valued at about $166,000. Hedge funds and other institutional investors own 25.84% of the company’s stock.
About Hyperion DeFi
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
Featured Articles
- Five stocks we like better than Hyperion DeFi
- MarketBeat Week in Review – 09/07 – 09/11
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
Receive News & Ratings for Hyperion DeFi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperion DeFi and related companies with MarketBeat.com's FREE daily email newsletter.
